Primary outcome in all patients in PRETa
| PRET-1 | PRET-2 | PRET | ||||
|---|---|---|---|---|---|---|
| Platinum (n = 124) | Hydrogel (n = 120) | Platinum (n = 96) | Hydrogel (n = 95) | Platinum (n = 220) | Hydrogel (n = 215) | |
| Primary outcome | 55 (44.4%) | 63 (52.5%) | 47 (49.0%) | 40 (42.1%) | 102 (46.4%) | 103 (47.9%) |
| Major recurrence | 33 (26.6%) | 35 (29.2%) | 33 (34.4%) | 25 (26.3%) | 66 (30.0%) | 60 (27.9%) |
| Retreatment | 11 (8.9%) | 19 (15.8%) | 10 (10.4%) | 6 (6.3%) | 21 (9.5%) | 25 (11.6%) |
| Initial treatment failure | 3 (2.4%) | 1 (0.8%) | 0 (0.0%) | 4 (4.2%) | 3 (1.4%) | 5 (2.3%) |
| SAH | 1 (0.8%) | 1 (0.8%) | 1 (1.0%) | 1 (1.1%) | 2 (0.9%) | 2 (0.9%) |
| Mass effect | 0 (0.0%) | 1 (0.8%) | 3 (3.1%) | 0 (0.0%) | 3 (1.4%) | 1 (0.5%) |
| Related mortality | 1 (0.8%) | 3 (2.5%) | 0 (0.0%) | 0 (0.0%) | 1 (0.5%) | 3 (1.4%) |
| Related morbidity | 2 (1.6%) | 1 (0.8%) | 0 (0.0%) | 1 (1.1%) | 2 (0.9%) | 2 (0.9%) |
| Last observation carried forwardb | 4 (3.2%) | 2 (1.7%) | 0 (0.0%) | 3 (3.2%) | 4 (1.8%) | 5 (2.3%) |